Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health | Small Molecules

Hits: 1077
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada
Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion
BASEL, Switzerland and NEW YORK, NY, USA I December 28, 2020 I Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology and women’s health in the U.S. and Canada. Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries.

Related Keywords

Canada ,Switzerland ,Andy Schmeltz ,Nick Lagunowich ,Lynn Seely ,Linkedin ,Myovant Sciences ,Women Health ,Drug Administration ,Myovant Sciences Conference Call ,I Myovant Sciences ,Pfizer ,Pfizer Inc ,Myovant Sciences Inc ,Sumitomo Dainippon Pharma Co Ltd ,Sumitovant Biopharma Ltd ,Pfizer Announce Collaboration ,Commercialize Relugolix ,United Statesi December ,Chief Executive Officer ,Global President ,Pfizer Internal ,New Drug Application ,Investor Relations ,Sumitovant Biopharma ,கனடா ,சுவிட்சர்லாந்து ,லின் பார்க்க ,சென்டர் ,பெண்கள் ஆரோக்கியம் ,ஃபைசர் ,ஃபைசர் இன்க் ,தலைமை நிர்வாகி அதிகாரி ,உலகளாவிய ப்ரெஸிடெஂட் ,ஃபைசர் உள் ,புதியது மருந்து விண்ணப்பம் ,முதலீட்டாளர் உறவுகள் ,